Quebec adds momentum to Canadian biosimilar switching
Generics Bulletin report on Quebec becoming the fourth province in Canada to announce a biosimilar switching policy.
Menu
Menu
Biosimilars news
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
Quebec announces a shift towards biosimilar drugs
Quebec has become the fourth province in Canada to announce its intention to implement a biosimilar switching policy. Quebec expects to generate annual savings of $100M and plans to reinvest the savings in the healthcare system and improve access to new therapies. Available in French only.
Quebec to cover only ‘biosimilar’ drugs, not name-brand biologics, in public drug plan
CTV News coverage of the Quebec Government’s plans to implement a biosimilar switching policy, which is expected to save the province more than $100 million annually.
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
Report from the American Journal of Managed Care on the addition of Humira adalimumab to Alberta’s biosimilar switching policy. About 3,300 patients will switch to adalimumab biosimilars over the next year.
Alberta expands biosimilar switching with adalimumab
Report from the Generics Bulletin on Alberta becoming the third province in Canada to apply its biosimilar switch policy to Humira adalimumab, the #2 top-selling biologic drug in Canada.
Update on biosimilars in Canada
The law firm Smart & Biggar recently published an overview of some key developments for biosimilars in Canada, including approvals, pending submissions and litigation. Health Canada has approved 36 biosimilars to date and has 16 biosimilar submissions under review.